Cargando…
Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma
The treatment landscape for metastatic melanoma has changed dramatically over the past few years as new medications have been developed. Encorafenib, a B-Raf protein kinase inhibitor, and binimetinib, a MEK inhibitor, were approved by the U.S. Food and Drug Administration in 2018 for the treatment o...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214962/ https://www.ncbi.nlm.nih.gov/pubmed/35755899 http://dx.doi.org/10.6004/jadpro.2022.13.4.7 |